ELI LILLY & CO (LLY) Stock News
NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock
LLY Latest News and Analysis
Obesity Drug Study Points to Effectiveness in Curbing Addictions
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their impact on the brain, pointing to benefits from addiction to schizophrenia.
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
Should You Buy the Dip in Eli Lilly Stock Right Now?
Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4.
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
Big Alcohol's fight, Costco's DEI defense, and Big Tech at the Trump show: Business news roundup
Plus, Eli Lilly was hoping weight loss drug demand would be even bigger
3 Unstoppable Stocks to Buy in 2025
Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. Eli Lilly now expects revenue to be approximately $13.5 billion for its fourth quarter and $45 billion for the full year 2024. The company had earlier forecast full-year revenue to come in between $45.4 billion to $46 billion.
Is Novo Nordisk Stock a Buy?
It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same pace it has been recently, its blockbuster drugs, specifically its weight loss drug Wegovy, need to continue to retain a sizable share of the market.
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.
Friday Sector Laggards: Utilities, Healthcare
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs.
Jim Cramer's top 10 things to watch in the stock market Friday
President Joe Biden won't enforce the TikTok ban, and very important price target cuts on Coca-Cola and PepsiCo shares.
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
Bond yield relief boosts 2 portfolio stocks — plus, a check on Eli Lilly after Tuesday's slide
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly.
See Which Of The Latest 13F Filers Holds Eli Lilly
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.
5 Things to Know Before the Stock Market Opens
News of the day for Jan. 15, 2025
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Tuesday's session: top gainers and losers in the S&P500 index
Top S&P500 movers in Tuesday's session
Which S&P500 stocks are moving on Tuesday?
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Gapping S&P500 stocks in Tuesday's session
Tuesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.